ReiThera at ESGCT 2026
Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website
ReiThera brings 5 presentations to ESGCT 2026 in Hamburg. Its contributions centre on manufacturing platforms for viral vectors, covering multi-serotype AAV production, suspension HEK293 lines for lentiviral vectors and poxvirus production in a duck cell line. One strand describes a gorilla-derived oncolytic adenovirus with natural lung tropism.
| Organization | ESGCT 2026 Attendance |
|---|---|
ReiThera Rome, Italy | |
Develops and manufactures genetic vaccines and viral vectors, offering adenoviral, AAV and MVA vector design through clinical-grade production. | Poster Wed Oct 28 1:30pm–3:30pm Recombinant MVA Generation and Purification Using a Duck Cell Line Poster Thu Oct 29 2:00pm–4:00pm A Scalable and Transferable Manufacturing Platform for Multi-Serotype AAV Vector Production Poster Thu Oct 29 2:00pm–4:00pm A novel Gorilla-derived oncolytic Adenovirus with natural lung tropism and selective replication in cancer cells Poster Thu Oct 29 2:00pm–4:00pm AdAAV: A Novel Transfection-Free Platform for High-Titer AAV Manufacturing Poster Thu Oct 29 2:00pm–4:00pm Development of ReiCell-LV, a Suspension HEK293 Platform for Enhanced Lentiviral Vector Production |
Instantly find 20 buyers from ReiThera
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction